🔗 Share this article

Given that the United States continues making sweeping revisions to its immunization recommendations, an unexpected name has emerged unexpectedly: Høeg, a US-based physician and public health researcher who first made her name by casting doubt on coronavirus vaccines during the global health crisis and has concentrated on possible fatalities after COVID-19 immunization in her recent tenure at the FDA.

Proposed Changes to Childhood Immunization Schedule

Agency leaders planned to reveal sweeping revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would place the US out of step with a large portion of the global community with insufficient data for public health gain. This reveal has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has little discernible track record in drug development, approval processes or administrative roles, which has been standard for former leaders of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Past heads of CBER would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she lacks the kind of background that previous people who ran the center have had.”

This division has an enormous workload at the agency, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and each of these have to be managed,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial management aspect to the position, which manages more than 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Agency Reaction and Disputed Initiatives

Regarding concerns about Høeg’s qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a representative responded that the “concerns rely on incorrect premises”.

“Her experience is consistent with the duties of her role,” the spokesperson stated, noting the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's recently launched expedited review system, a contentious rapid medication authorization process that apparently troubled her predecessors. “How are these medications being chosen for this fast-track system? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of all drugs, except for vaccines.”

Established History on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, history, critics said. She authored a study using unverified crowd-sourced reports to estimate the rate of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current federal leadership encompassed changing regulations for new vaccines and discontinuing “non-essential” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from getting Covid vaccinations.

“She’s an thorough dogmatist who commences with her beliefs and tailors the evidence to accommodate the evidence in a highly disingenuous, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|